About
pH-Activated Compounds
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
273
By Phase
PHASE1: 1PHASE2: 3
By Status
COMPLETED: 3RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06022029Lead Sponsor
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
PHASE1Recruiting
168 participants
Started: Oct 13, 2023 · Completed: Aug 29, 2026
NCT05048082Lead Sponsor
A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies
PHASE2Completed
24 participants
Started: Apr 13, 2022 · Completed: Aug 31, 2022
NCT04950166Lead Sponsor
A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
PHASE2Completed
51 participants
Started: Nov 30, 2021 · Completed: Jan 20, 2023
NCT03735680Lead Sponsor
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
PHASE2Completed
30 participants
Started: Aug 9, 2019 · Completed: Nov 18, 2021
Locations (1)
Headquarters
Dallas, TX, United States
Map
Loading map...